Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, al ...
Abstract: This paper provides an overview of emerging applications which will drive innovation in the MEMS industry for many years to come. Examples range from highly accurate inertial MEMS for future ...
The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback